DOC Updates

Over two decades ago, Lipoprotein(a)—or Lp(a)—was recognized as an emerging risk factor for cardiovascular disease. In this special edition of DOC Updates, Dr. Neil Skolnik explores our growing understanding of this cholesterol-carrying lipoprotein.
This special episode is sponsored with support from Lilly.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
EPISODE NOTES
Special Edition: Special Edition: Lp(a) & CV Risk
In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Michael Wilkinson, who goes over the history of Lp(a), the current guidelines, and the importance of screening.
This special episode is sponsored with support from Lilly.
Presented by:
-Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
-Michael Wilkinson, MD, Associate Professor of Medicine at University of California San Diego Health, and Director of the advanced lipid treatment program at UC San Diego Health, Board of Directors of the National Lipid Association and Associate editor of the American Journal of Preventive Cardiology
References:
-The American Heart Association PREVENT Online Calculator
-Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects – Circulation 2025; 151:400-415
-2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation Volume 153, Issue 17, 28 April 2026; Pages e1154-e1276

Continuing his exploration of once-weekly insulins, Neil Skolnik speaks with Aaron King, MD. Together, they cover the mechanisms, practical considerations, and the myriad benefits that this new therapy can have over daily basal insulin.
This special episode is sponsored with support from Novo.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Aaron King, MD. Trained in the United States Navy in Family Medicine and certified by the American College of Diabetology, Dr. King practices outpatient diabetes management in San Antonio, Texas.
Selected references:
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med 2023;389:297-308
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. N Engl J Med 2025;393:325-335

There is a fundamental link between diabetes and kidney care. But while there are many medications available to improve CKD outcomes in people with type 2 diabetes, the same options are not available for people with type 1. In this special episode, Dr. Neil Skolnik speaks with Janet McGill, MD, MA, FACE, FACP about the underdiscussed prevalence of CKD in type 1 and the importance of continued development in this area.
This special episode is sponsored with support from Bayer.
Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Janet B. McGill, MD, MA, FACE, FACP, Professor of Medicine at the University of Washington's John T. Milliken Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research
Selected References:
Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260
Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med 2026;394:947-957
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229
Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Welcome to the latest episode (July 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.
This month on DOC Updates:
Aroda V, Buzzetti R, Dalskov S et al. "Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9

Bajaj H, Welch M, Shah P et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0

Melville, N. "CGM Monitoring Benefits Extend to Non-Insulin-Using T2D." Medscape, June 07, 2026

Aronne, L.J., Horn, D.B., le Roux, C.W. et al. "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial." Nat Med(2026) doi: 10.1038/s41591-026-04386-7

Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes." JAMA. Published online June 15, 2026. doi:10.1001/jama.2026.8492

Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

In this special edition of DOC Updates, Neil Skolnik speaks with Dr. Juan Frias, who catalogues the latest cardiometabolic medications, emphasizing the distinguishing characteristics of each.
This special episode is sponsored with support from Lilly.
Presented by:
Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health
Juan Pablo Frias, MD, Medical Director and Principal Investigator, Los Angeles Institute for Metabolic Research, Adjunct Professor of Medicine at Charles Drew University of Medicine and Science